Literature DB >> 2896213

IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.

D J Peace1, D E Kern, K R Schultz, P D Greenberg, M A Cheever.   

Abstract

The purpose of the current study was to characterize lymphokine-activated killer (LAK) activity induced with IL-4/B cell stimulatory factor-1 and to compare IL-4-induced LAK activity with IL-2-induced LAK activity. Culture of murine lymphocytes with high concentrations of IL-4 induced nonspecific lytic activity against a wide variety of tumors. Lytic activity induced by IL-4 increased with increasing concentrations of IL-4 over the range of 1.0 to 25 ng/ml. The kinetics of LAK induction by IL-4 and IL-2 were similar; however, IL-4 was less effective than IL-2 in maintaining lytic activity for longer culture periods and provided lower viable cell yields than did IL-2. Similar to IL-2, IL-4 induced blastogenesis and the generation of large granular lymphocytes, all LAK activity observed was exclusively associated with the large granular lymphocyte fraction, and the cytolytic effector cells were heterogeneous in regards to cell surface phenotype. The majority of IL-4-induced lytic activity was associated with mutually exclusive NK-like (i.e., NK-1.1+ Lyt-2-) and T cell-like (i.e., NK-1.1- Lyt-2+) LAK cells. The precursors for each subset were distinct and expressed the asialo-GM1+ Lyt-2- and the asialo-GM1+ Lyt-2+ phenotypes, respectively. Although IL-4-induced LAK effector cells were morphologically and phenotypically similar to IL-2-induced LAK cells, IL-2 generated equivalent numbers of T cell-like and NK-like LAK cells, whereas IL-4 generated 3.5-fold more T cell-like LAK cells than NK-like LAK cells. It might eventually be possible to exploit the preferential activation of T cell-like LAK by IL-4 for therapeutic advantage.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896213

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).

Authors:  G Pawelec; E Schneider; G Ehninger; A Rehbein; H Schmidt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell line.

Authors:  Erian Girgis; John Mahoney; Selina Darling-Reed; Magdi Soliman
Journal:  Oncol Lett       Date:  2010-05       Impact factor: 2.967

3.  Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  P Wersäll; G Masucci; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Authors:  D W Beno; H L Mathews
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

5.  Roles for interleukin-2 (IL-2) and IL-4 in the generation of allocytotoxic T cells in the primary and secondary responses in vitro.

Authors:  H Suzuki; I S Tunru; A Yokoyama
Journal:  Experientia       Date:  1992-03-15

6.  Induction of lymphokine-activated killer cells from nude mouse spleen cells by interleukin-4.

Authors:  I S Tunru; H Suzuki; M Kobayashi
Journal:  Experientia       Date:  1993-01-15

7.  Cytokines regulate the ability of human LAK-cells to kill human tumour cells in vitro.

Authors:  G Gallagher; F al-Azzawi; J Davis; W H Stimson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

8.  IL-1 and IL-4 as reciprocal regulators of IL-2 induced lymphocyte cytotoxicity.

Authors:  N Ebina; D Gallardo; H Shau; S H Golub
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

9.  EC-18, a synthetic monoacetyldiacylglyceride, inhibits hematogenous metastasis of KIGB-5 biliary cancer cell in hamster model.

Authors:  Myung-Hwan Kim; Heung Moon Chang; Tae Won Kim; Sung Koo Lee; Jung-Sun Park; Young-Hoon Kim; Tae Yoon Lee; Se Jin Jang; Chul-Won Suh; Tae-Suk Lee; Sang-Hee B Kim; Sung-Gyu Lee
Journal:  J Korean Med Sci       Date:  2009-06-12       Impact factor: 2.153

10.  Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.

Authors:  D J Peace; J W Smith; W Chen; S G You; W L Cosand; J Blake; M A Cheever
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.